Bone tumours.

摘要

Thirty to 40 years ago, the development of new imaging techniques, the introduction of highly effective chemotherapy and the progression of reconstruction surgery by using new modular design of tumour endoprostheses all resulted in the implementation of limb-saving surgery and fundamentally altered our philosophy about the treatment of highly malignant bone tumours.Although such basic changes have not been observed since then, it is important to re-evaluate the results from time to time to obtain evidence of the results with different treatment protocols.The first two articles in this special issue are review articles. Rozeman, Cleton-Jansen and Hogendoorn from Leiden, The Netherlands, summarise the state of art of our knowledge about the pathology of primary malignant bone-forming and cartilage tumours. Carrie and Bielack from Stuttgart, Germany, focus in their article on the current chemotherapy regimens in conventional osteosarcoma and in it's variants, like small-cell surface osteosarcomas or secondary osteosarcomas. Chemotherapy for poor respondersand in older patients is also discussed here on the basis of the results of COSS, the German-Austrian-Swiss Cooperative Osteosarcoma Study Group, a multicentre study which evaluates the treatment results of osteosarcoma patients out of a 100-million population.